Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02766959 · ClinicalTrials.gov registry record
Allele-specific Expression of a Bitter Taste Receptor
A clinical trial, sponsored by Monell Chemical Senses Center.
- Completed
- Registry status
- 57
- Enrollment target
NCT02766959: Completed study, sponsored by Monell Chemical Senses Center.
NCT02766959 is a clinical trial that has completed, run by Monell Chemical Senses Center. The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02766959 has completed, sponsored by Monell Chemical Senses Center.
- COMPLETED
- Registry status
- 57 participants
- Enrollment target
Study Summary
This single-site, within-subject experimental basic research study is designed to analyze the hypothesis that allele-specific expression of the bitter taste receptor T2R38 in taste tissue of individuals heterozygous for the taste receptor gene TAS2R38 correlates with that in nasal epithelium, and is responsible for differences in acyl-homoserine lactone-induced respiratory defenses. Subjects will include 100 predominantly European adults without chronic rhinosinusitis who will be undergoing a sinonasal procedure for reconstructive purposes. All subjects will provide saliva samples for genotyping, from which 25 subjects heterozygous for TAS2R38 (AVI/PAV) will be identified. These individuals will be asked to complete a beverage frequency questionnaire and taste test prior to the procedure that will evaluate for a number of compounds, among them bitter ligands specific to T2R38. Their tongue will also be photographed to evaluate the anatomy of their fungiform papillae, the mushroom-like structures on the tongue which contain taste buds. Subjects will subsequently provide nasal epithelium and taste tissue, which will be processed to 1) evaluate for allele-specific expression of TAS2R38 mRNA in both the taste and nasal tissue, with the nasal tissue concurrently being cultured in an air-liquid interface system to 2) assess the AHL-induced respiratory defenses of ciliary beat frequency (CBF) and nitric oxide (NO) production. Should subjects require a subsequent sinonasal procedure for clinically-determined reasons, taste and nasal tissue will again be obtained and analyzed for TAS2R38 mRNA, allowing for 3) longitudinal evaluation of mRNA expression level.
Primary Outcome
A participant's genotype will be identified on enrollment in the study, the results of which could take up to 1 month to be performed.
Interventions
- OTHER Observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2016-01 |
| Est. Completion | 2018-08 |
What the finished NCT02766959 record still lists
NCT02766959 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 57 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Observational study is the first listed.
NCT02766959 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02766959 about?
NCT02766959 is a clinical study titled "Allele-specific Expression of a Bitter Taste Receptor". This single-site, within-subject experimental basic research study is designed to analyze the hypothesis that allele-specific expression of the bitter taste receptor T2R38 in taste tissue of individuals heterozygous for the taste receptor gene TAS2R38 correlates with that in nasal epithelium, and is...
What is the current status of trial NCT02766959?
This trial is currently completed. The enrollment target is 57 participants. The study started on 2016-01. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02766959?
The interventions under investigation include: Observational study (OTHER).
Who is sponsoring clinical trial NCT02766959?
This trial is sponsored by Monell Chemical Senses Center, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia